These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 26981243)

  • 41. The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.
    Simmons D; Lang E
    Cureus; 2017 Oct; 9(10):e1774. PubMed ID: 29250474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy.
    Ileana Dumbrava E; Smith V; Alfattal R; El-Naggar AK; Penas-Prado M; Tsimberidou AM
    J Immunother; 2018 Sep; 41(7):336-339. PubMed ID: 29787423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurosarcoidosis following Immune Checkpoint Inhibition.
    Dunn-Pirio AM; Shah S; Eckstein C
    Case Rep Oncol; 2018; 11(2):521-526. PubMed ID: 30186134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding Immune Checkpoint Inhibitors for Effective Patient Care.
    Rubin KM
    Clin J Oncol Nurs; 2015 Dec; 19(6):709-17. PubMed ID: 26583635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
    Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
    Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identifying and managing the adverse effects of immune checkpoint blockade.
    Winer A; Bodor JN; Borghaei H
    J Thorac Dis; 2018 Feb; 10(Suppl 3):S480-S489. PubMed ID: 29593893
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.
    Teixidor E; Sais E; Vásquez CA; Carbajal W; Hernández A; Sánchez G; Izquierdo A; Verdura S; Menéndez JA; Bosch-Barrera J
    Oncotarget; 2018 Aug; 9(68):33043-33049. PubMed ID: 30250648
    [TBL] [Abstract][Full Text] [Related]  

  • 50. An autopsy case of immune-related severe colitis due to long-term use of nivolumab in a patient with non-small cell lung cancer.
    Fujikawa M; Tajiri T; Takemura M; Nakao K; Yamamoto S; Takeda N; Fukumitsu K; Fukuda S; Kamemitsu Y; Uemura T; Ohkubo H; Maeno K; Ito Y; Oguri T; Niimi A
    Respir Med Case Rep; 2022; 39():101720. PubMed ID: 35993006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. THYROID DYSFUNCTION, RECOVERY, AND PROGNOSIS IN MELANOMA PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A RETROSPECTIVE REVIEW.
    Al Mushref M; Guido PA; Collichio FA; Moore DT; Clemmons DR
    Endocr Pract; 2020 Jan; 26(1):36-42. PubMed ID: 31461358
    [No Abstract]   [Full Text] [Related]  

  • 52. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary Biliary Cirrhosis and Granulomatous Hepatitis After Immune Checkpoint Blockade in Patients With Metastatic Melanoma: Report of 2 Cases and Literature Discussion.
    Ruini C; Haas C; Mastnik S; Knott M; French LE; Schlaak M; Berking C
    J Immunother; 2021 Feb-Mar 01; 44(2):71-75. PubMed ID: 33323872
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.
    Hasan Ali O; Diem S; Markert E; Jochum W; Kerl K; French LE; Speiser DE; Früh M; Flatz L
    Oncoimmunology; 2016; 5(11):e1231292. PubMed ID: 27999741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.
    Kamath SD; Kumthekar PU
    Front Oncol; 2018; 8():414. PubMed ID: 30319977
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation.
    Cooling LL; Sherbeck J; Mowers JC; Hugan SL
    Immunohematology; 2017 Jan; 33(1):15-21. PubMed ID: 28425751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.